更强的I型干扰素特征可区分ANCA相关性血管炎表型并预测肾脏预后
该研究对193例ANCA相关性血管炎(AAV)伴肾小球肾炎患者进行肾脏转录组分析,发现MPA/MPO-AAV的肾脏I型干扰素(IFN-I)特征较GPA/PR3-AAV和对照上调,且与肾脏纤维化及肾脏生存率降低相关,提示IFN-I可能作为预后生物标志物和治疗靶点。
要点
- MPA/MPO-AAV肾脏IFN-I特征较GPA/PR3-AAV和对照上调
- 肾脏IFN-I激活与肾脏纤维化增加相关,独立于肾功能
- 高肾脏IFN-I特征与较低肾脏生存率相关,独立于肾功能和病理评分
核心结论
- AAV中存在IFN-I特征,尤其在MPA/MPO-AAV中更明显,提示其在疾病异质性和肾脏病理中可能发挥作用。
- IFN-I可能作为AAV尤其是MPA的预后生物标志物和治疗靶点,需进一步研究阐明机制并在临床试验中探索IFN-I调节。
研究设计与样本
- 研究分析两个独立队列(Maine-Anjou和RENVAS注册库)共193例AAV伴肾小球肾炎患者。
- 采用NanoString nCounter转录组分析和血清炎症分子定量,并用独立公共数据集(包括肾脏空间转录组数据集、欧洲cDNA肾脏生物样本库和RAVE试验血液)验证MPA vs GPA及MPO-AAV vs PR3-AAV的比较分析。
主要发现
- AAV-GN中肾脏IFN-I特征在MPA/MPO-AAV中较GPA/PR3-AAV和对照上调,经定量PCR、MxA免疫组化和外部数据集分析证实。
- 该IFN-I特征与狼疮肾炎中所见相近,与pDC浸润程度相关。
- 肾脏IFN-I激活与肾脏纤维化增加相关,独立于肾功能。
- 高肾脏IFN-I特征与较低肾脏生存率相关,独立于肾功能和病理评分。
- MPA肾脏还显示更高的肥大细胞和T细胞浸润;系统性分析显示所有AAV患者IFNα和干扰素相关炎症分子升高,但MPA免疫细胞中IFN-I基因特征更强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以阐明其机制并在临床试验中探索IFN-I调节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) causes severe multisystemic organ damage. The main phenotypes, microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), share similarities but differ in clinical presentation and outcome. To uncover their molecular differences, we performed transcriptomic profiling of kidney tissue, then focused on type I interferon (IFN-I) pathway activation in kidney and blood and its clinical implications. METHODS: We analyzed two independent cohorts (Maine-Anjou and RENVAS registries) totaling 193 patients with AAV and glomerulonephritis. NanoString nCounter transcriptomic profiling, and serum inflammatory molecules quantification were conducted. Comparative analyses of MPA vs. GPA (and MPO-AAV vs. PR3-AAV) were validated using independent public datasets (including kidney spatial transcriptomic datasets, European cDNA Renal Biobank and blood from the RAVE trial). RESULTS: The kidney IFN-I signature found in AAV-GN is upregulated in MPA/MPO-AAV compared to GPA/PR3-AAV and controls. Quantitative PCR, MxA immunohistochemistry, and analysis of external datasets confirmed these findings. This IFN-I signature, close to the one found in lupus nephritis, is linked to the extent of pDC infiltration. Kidney IFN-I activation correlated with increased kidney fibrosis, independently of kidney function. High kidney IFN-I signatures were linked to lower kidney survival, independently of kidney function and pathological scores. MPA kidneys also exhibited higher mast cell and T-cell infiltration. Systemic analyses showed elevated IFNα and interferon related inflammatory molecules in all patients with AAV, but a stronger IFN-I gene signature was found in immune cells from MPA. CONCLUSIONS: Our study identifies an IFN-I signature in AAV, especially in MPA/MPO-AAV, underscoring its potential role in disease heterogeneity and kidney pathology. IFN-I emerges as a potential prognostic biomarker and therapeutic target in AAV, particularly for MPA. Further studies are needed to clarify its mechanisms and explore IFN-I modulation in clinical trials.
引用
- Brilland B, Despré M, Khatri R, et al. A stronger type I interferon signature distinguishes ANCA-associated vasculitis phenotypes and predicts kidney prognosis. Kidney Int. 2025. PMID: 40935134. doi:10.1016/j.kint.2025.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。